NRx Pharmaceuticals, Inc. Share Price & Technical Analysis
NRXP · $3.22 (+5.23%)
Healthcare / Biotechnology
$3.22
+5.23%
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone …
Price chart
Seasonality
May has 4 positive and 1 negative years (last 5 years shown)
7% return in May, 43% avg return in past 3 year May month.
25% return in 2026, 1% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -25% | -10% | 17% | 36% | 7% | – | – | – | – | – | – | – | 25% |
| 25 | 43% | -23% | -13% | 0% | 24% | 22% | -16% | -15% | 43% | -6% | -17% | 13% | 55% |
| 24 | -20% | -3% | 27% | -45% | 81% | -40% | -4% | -17% | -11% | -18% | -7% | 69% | 13% |
| 23 | 3% | -14% | -35% | -11% | 23% | -33% | -19% | -25% | -13% | 19% | 10% | 31% | -65% |
| 22 | -37% | -1% | -16% | -37% | -63% | 0% | 39% | -31% | 9% | 8% | 78% | -26% | -78% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Strong
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$93.09M
P/E ratio
—
52W high
$3.84
52W low
$1.62
Volume
14,84,089
Beta
2.02
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is NRx Pharmaceuticals, Inc. share price today?
- NRx Pharmaceuticals, Inc. (NRXP) last traded around $3.22 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does NRXP have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for NRXP. Download the app for real-time alerts.
- How can I analyze NRx Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.